Filing Flows › Integra Lifesciences Holdings (IART) › Q2 2026
Integra Lifesciences Holdings (IART) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 29, 2026
Integra Lifesciences Holdings (IART) reported revenue of $419M for the second quarter 2026 (Q2 2026), +0.8% from a year earlier and +7% from the quarter before. Operating margin was 4.6%, net earnings $4.5M (1.1% of revenue).
Integra Lifesciences Holdings, Q2 2026: revenue $419M (+0.8% year over year), operating margin 4.6%, net earnings $4.5M, operating cash flow $22.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $419M | +7% | +0.8% |
| Operating profit | $19.3M | +68% | — |
| Net earnings | $4.5M | — | — |
| Operating cash flow | $22.8M | +133% | +156% |
| Free cash flow | $10.5M | — | — |
What changed
Revenue was $418.8M in Q2 2026, up 1% year over year and up 7% from the previous quarter. Specialty Surgery was the largest line at 74% of revenue. Specialty Surgery added $5.3M year over year (up 2%), 168% of the total change. Tissue Reconstruction declined 2%.
Operating profit was $19.3M, a 4.6% margin (up 128.0 points year over year). Total costs fell 57% while revenue rose 1%. Net earnings were $4.5M. The effective tax rate was 5.5%.
Operating cash flow was $22.8M (up 156% year over year), 509% of net earnings. Non-cash charges added back $5.8M of share-based compensation. Working capital and other items added $12.5M. After purchases of property and equipment ($12.3M), free cash flow as the company reports it was $10.5M.
Questions
What was Integra Lifesciences Holdings' revenue in the second quarter 2026?
Integra Lifesciences Holdings (IART) reported revenue of $419M for the second quarter 2026 (Q2 2026), +0.8% from a year earlier and +7% from the quarter before.
Was Integra Lifesciences Holdings profitable in the second quarter 2026?
Operating profit was $19.3M (4.6% of revenue) and net earnings $4.5M.